









Registered Address: Chemicea Pharmaceuticals Pvt Ltd, Platinum Springs,

Unit No- A- 205&206 Second floor, Plot No: G-6, G-20 to G 24, Taloja- MIDC, Opp. Dena Bank

Navi Mumbai 410208, MH, INDIA. Email- info@chemicea.com Mob- +91 9284897978

## **CERTIFICATE OF ANALYSIS**

Analysis Date: Aug 2024 Re-test Date: Jul 2027

**Product Name: Rapamycin (In House Standard)** 

## **Identification:**

Chemical Name: (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-

9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-

c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Synonyms : Supralimus ; 14S-Rapamycin ;

Sirolimus

CAS Number : 53123-88-9

CAT Number : CP-R26000

Molecular Formula : C51H79NO13

Molecular Weight : 914.19

Batch Number : CP-RAP-IN-0824

Storage Condition : Tightly closed, Inert atmosphere at 2 to 8° C

Shipping condition : All Products are stable to be shipped at room temperature, if specific condition required it is

mention in the COA

# **Analytical Information:**

| Sr. No. | Test           | Result                   |
|---------|----------------|--------------------------|
| 1)      | Description    | White Solid              |
| 2)      | Solubility     | Soluble in Methanol/DMSO |
| 3)      | MASS By LCMS   | Confirm to structure     |
| 4)      | Purity By HPLC | 99.04%                   |
| 5)      | H1NMR          | Confirm to structure     |
| 6)      | 13CNMR         | Confirm to structure     |



## **Prepared and Reviewed By**

Line of

Ms Priyanka Salunkhe (Manager QC Analytical)

## **Approved By**



Ms Rohini Gagare (QA Head)

| Note: Product supplied by Chemicea are for R&D purpose only and not for human consumptions. |  |  |  |  |
|---|--|--|--|--|
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |
|   |  |  |  |  |